4
Changes in Ownership
MADRIGAL PHARMACEUTICALS, INC. Filed Acc 0000899243-23-006751
Senior VP, Chief Pharma Dev. sold 10,000 shares at an average $273.24 ($2,732,438)
- Senior VP, Chief Pharma Dev. acquired 10,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-02-28 | Option exercise | +5,000 | $87.92 | $439,600 | 10,667 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-02-28 | Sale | −900 | $271.03 | $243,927 | 9,767 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-02-28 | Sale | −4,100 | $272.30 | $1,116,430 | 5,667 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-03-01 | Option exercise | +5,000 | $87.92 | $439,600 | 10,667 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-03-01 | Sale | −1,928 | $273.44 | $527,192 | 8,739 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-03-01 | Sale | −1,672 | $274.57 | $459,081 | 7,067 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-03-01 | Sale | −1,300 | $275.53 | $358,189 | 5,767 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-03-01 | Sale | −100 | $276.19 | $27,619 | 5,667 | D |
| Derivatives | |||||||
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-02-28 | Option exercise · Stock Option (Right to Buy) | −5,000 | 30,000 | D | ||
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-03-01 | Option exercise · Stock Option (Right to Buy) | −5,000 | 25,000 | D | ||
| Open-market sales · 10,000 sh · avg $273.24 · $2,732,438 | |||||||
Loading xslF345X03/doc4.xml…